Pharmafile Logo
Pharmafocus logo
Advanced Search

mergers & acquisitions

Showing 3 posts of 3 posts found.

Abbvie acquires Cerevel Therapeutics

August 2, 2024
Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia

Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …

News

Funding overview for the pharmaceutical industry and outlook for 2020

March 2, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, M&A, MA, feature, mergers & acquisitions, opinion, pharma

This article was originally published in the January/February 2020 issue of Pharmafocus.With the advent of a New Year, Michael Jewell, …

Feature

Transactions in the pharma sector: Through the EU merger review looking-glass

December 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …

Feature
The Gateway to Local Adoption Series

Latest content

Product value to pathway impact: What the CVD Modern Service Framework means for pharma

August 9, 2026

Functional lung imaging offers new possibilities for respiratory care

August 9, 2026

Five Facts about cardiovascular disease

August 9, 2026

Data integrity: the keystone for AI adoption, patient safety and organisational reputation

August 9, 2026

Artificial hearts: a century of innovation

August 9, 2026